Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma

Profound intratumoral genomic heterogeneity has limited the ability of targeted therapies to overcome therapy resistance in glioblastoma. We have defined purine metabolism as a key mediator of DNA repair and radiation resistance in glioblastoma. Because many glioblastoma oncogenic drivers activate p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Weihua, Wahl, Daniel R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671052/
https://www.ncbi.nlm.nih.gov/pubmed/33235923
http://dx.doi.org/10.1080/23723556.2020.1834902
_version_ 1783610854487359488
author Zhou, Weihua
Wahl, Daniel R
author_facet Zhou, Weihua
Wahl, Daniel R
author_sort Zhou, Weihua
collection PubMed
description Profound intratumoral genomic heterogeneity has limited the ability of targeted therapies to overcome therapy resistance in glioblastoma. We have defined purine metabolism as a key mediator of DNA repair and radiation resistance in glioblastoma. Because many glioblastoma oncogenic drivers activate purine metabolism, its inhibition may overcome therapy resistance despite intratumoral genomic heterogeneity.
format Online
Article
Text
id pubmed-7671052
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-76710522020-11-23 Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma Zhou, Weihua Wahl, Daniel R Mol Cell Oncol Commentary Profound intratumoral genomic heterogeneity has limited the ability of targeted therapies to overcome therapy resistance in glioblastoma. We have defined purine metabolism as a key mediator of DNA repair and radiation resistance in glioblastoma. Because many glioblastoma oncogenic drivers activate purine metabolism, its inhibition may overcome therapy resistance despite intratumoral genomic heterogeneity. Taylor & Francis 2020-10-27 /pmc/articles/PMC7671052/ /pubmed/33235923 http://dx.doi.org/10.1080/23723556.2020.1834902 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Commentary
Zhou, Weihua
Wahl, Daniel R
Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma
title Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma
title_full Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma
title_fullStr Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma
title_full_unstemmed Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma
title_short Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma
title_sort purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671052/
https://www.ncbi.nlm.nih.gov/pubmed/33235923
http://dx.doi.org/10.1080/23723556.2020.1834902
work_keys_str_mv AT zhouweihua purinemetabolismpromotesradioresistanceandisatherapeutictargetinglioblastoma
AT wahldanielr purinemetabolismpromotesradioresistanceandisatherapeutictargetinglioblastoma

Ejemplares similares